DK2854850T3 - Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom - Google Patents
Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom Download PDFInfo
- Publication number
- DK2854850T3 DK2854850T3 DK13793069.9T DK13793069T DK2854850T3 DK 2854850 T3 DK2854850 T3 DK 2854850T3 DK 13793069 T DK13793069 T DK 13793069T DK 2854850 T3 DK2854850 T3 DK 2854850T3
- Authority
- DK
- Denmark
- Prior art keywords
- syndrome
- prevention
- compositions
- treatment
- radiation disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651729P | 2012-05-25 | 2012-05-25 | |
| PCT/US2013/042941 WO2013177596A2 (en) | 2012-05-25 | 2013-05-28 | Methods for treating gi syndrome and graft versus host disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2854850T3 true DK2854850T3 (da) | 2021-08-30 |
Family
ID=49624550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13793069.9T DK2854850T3 (da) | 2012-05-25 | 2013-05-28 | Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10722577B2 (da) |
| EP (2) | EP2854850B1 (da) |
| JP (4) | JP6257600B2 (da) |
| AU (1) | AU2013266069B2 (da) |
| CA (2) | CA3172599C (da) |
| DK (1) | DK2854850T3 (da) |
| ES (1) | ES2879931T3 (da) |
| WO (1) | WO2013177596A2 (da) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| SG11201503966PA (en) | 2012-11-23 | 2015-06-29 | Seres Health Inc | Synergistic bacterial compositions and methods of production and use thereof |
| JP2016509003A (ja) | 2013-02-04 | 2016-03-24 | セレス セラピューティクス インコーポレイテッド | 組成物および方法 |
| WO2014145958A2 (en) | 2013-03-15 | 2014-09-18 | Seres Health, Inc. | Network-based microbial compositions and methods |
| US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
| JP2016538270A (ja) | 2013-10-25 | 2016-12-08 | ファーマサイクリックス エルエルシー | 移植片対宿主病を処置し予防する方法 |
| CN105979952B (zh) | 2013-11-25 | 2022-04-08 | 赛里斯治疗公司 | 协同细菌组合物以及其制造方法和用途 |
| TW202228700A (zh) * | 2013-12-02 | 2022-08-01 | 美商製藥公司 | 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法 |
| WO2016022883A1 (en) * | 2014-08-07 | 2016-02-11 | Memorial Sloan-Kettering Cancer Center | Anti-ceramide antibodies |
| WO2016086161A1 (en) * | 2014-11-25 | 2016-06-02 | Memorial Sloan-Kettering Cancer Center | Intestinal microbiota and gvhd |
| WO2017023863A1 (en) | 2015-07-31 | 2017-02-09 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
| EP3365027B1 (en) | 2015-10-14 | 2022-03-30 | Research Institute at Nationwide Children's Hospital | Hu specific antibodies and their use in inhibiting biofilm |
| US20180346571A1 (en) * | 2015-11-17 | 2018-12-06 | Oncomed Pharmaceuticals, Inc. | Pd-l1-binding agents and uses thereof |
| JP7661008B2 (ja) | 2017-01-04 | 2025-04-14 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | バイオフィルム関連障害の処置のための抗体断片 |
| US11564982B2 (en) | 2017-01-04 | 2023-01-31 | Research Institute At Nationwide Children's Hospital | DNABII vaccines and antibodies with enhanced activity |
| EP3668527A1 (en) | 2017-08-14 | 2020-06-24 | Seres Therapeutics, Inc. | Compositions and methods for treating cholestatic disease |
| BR112020008552A2 (pt) | 2017-10-30 | 2020-12-29 | Seres Therapeutics, Inc. | métodos e composições para tratamento de resistência a antibiótico |
| JP2021534196A (ja) | 2018-08-23 | 2021-12-09 | シージェン インコーポレイテッド | 抗ｔｉｇｉｔ抗体 |
| AU2019354829B2 (en) | 2018-10-05 | 2025-04-17 | Research Institute At Nationwide Children's Hospital | Hmgb1 protein derivatives for the removal of biofilms |
| US20220023419A1 (en) * | 2018-11-28 | 2022-01-27 | The Council Of The Queensland Institute Of Medical Research | Inhibiting inflammation |
| CN110237075A (zh) * | 2019-06-25 | 2019-09-17 | 华中农业大学 | 一种达氟沙星在治疗副猪嗜血杆菌药物中的用途 |
| AU2020311897A1 (en) | 2019-07-08 | 2022-02-03 | Research Institute At Nationwide Children's Hospital | Antibody compositions for disrupting biofilms |
| CA3183196A1 (en) * | 2020-07-07 | 2022-01-13 | Steven D. Goodman | Combination therapies for the treatment and prevention of biofilms |
| EP4308231A4 (en) * | 2021-03-16 | 2025-01-29 | Memorial Sloan Kettering Cancer Center | IMPROVING WOUND HEALING WITH ANTI-CERAMIDE ANTIBODIES |
| KR20250156322A (ko) * | 2024-04-25 | 2025-11-03 | 한국 한의학 연구원 | 트로바플록사신을 유효성분으로 함유하는 항암제 내성암의 예방 또는 치료용 약학 조성물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4950649A (en) * | 1980-09-12 | 1990-08-21 | University Of Illinois | Didemnins and nordidemnins |
| JPH02128697A (ja) | 1988-11-09 | 1990-05-17 | Hoechst Japan Ltd | 抗フコシルセラミドモノクローナル抗体 |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| EP0937258A2 (en) | 1996-10-29 | 1999-08-25 | Fred Hutchinson Cancer Research Center, Inc. | Cell stress regulated human mhc class i gene |
| JP4398620B2 (ja) * | 2000-02-03 | 2010-01-13 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | ヒト化抗ｃｃｒ−２抗体およびその使用方法 |
| AU2002211681A1 (en) | 2000-10-12 | 2002-04-22 | Curagen Corporation | Proteins and nucleic acids encoding same |
| US20040109855A1 (en) * | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| DE10239531A1 (de) | 2002-08-23 | 2004-03-04 | Gulbins, Erich, Prof. Dr. | Prophylaxe und Therapie von Infektionserkrankungen |
| WO2005025489A2 (en) | 2003-05-09 | 2005-03-24 | Curagen Corporation | Therapeutic use of g53135-05(fgf-20) in radiation protection |
| AR044388A1 (es) * | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| KR100565437B1 (ko) | 2003-07-31 | 2006-03-30 | 중앙대학교 산학협력단 | 신규한 스핑고마이엘리나제 효소, 그에 대한 항체, 안티센스 및 제조방법 |
| JP2008546647A (ja) | 2005-06-08 | 2008-12-25 | デューク ユニバーシティ | 移植のための抗−ｃｄ１９抗体治療 |
| CN101421393B (zh) * | 2006-02-14 | 2013-08-14 | 塞勒兰特治疗公司 | 提高造血干细胞植入的方法和组合物 |
| JP5924863B2 (ja) * | 2007-05-06 | 2016-05-25 | スローン ケタリング インスティテュート フォア キャンサー リサーチ | Ｇｉ症候群及び移植片対宿主病を治療及び予防する方法 |
| SG10201704531XA (en) | 2008-12-08 | 2017-07-28 | Soligenix Inc | Topically active steroids for use in radiation and chemotherapeutics injury |
-
2013
- 2013-05-28 AU AU2013266069A patent/AU2013266069B2/en active Active
- 2013-05-28 JP JP2015514243A patent/JP6257600B2/ja active Active
- 2013-05-28 US US14/402,875 patent/US10722577B2/en active Active
- 2013-05-28 ES ES13793069T patent/ES2879931T3/es active Active
- 2013-05-28 WO PCT/US2013/042941 patent/WO2013177596A2/en not_active Ceased
- 2013-05-28 CA CA3172599A patent/CA3172599C/en active Active
- 2013-05-28 DK DK13793069.9T patent/DK2854850T3/da active
- 2013-05-28 EP EP13793069.9A patent/EP2854850B1/en active Active
- 2013-05-28 CA CA2874673A patent/CA2874673C/en active Active
- 2013-05-28 EP EP21164357.2A patent/EP3903820B1/en active Active
-
2017
- 2017-10-06 JP JP2017196387A patent/JP6761792B2/ja active Active
-
2019
- 2019-04-10 JP JP2019075155A patent/JP7072538B2/ja active Active
-
2020
- 2020-07-17 US US16/932,204 patent/US20220118087A1/en not_active Abandoned
-
2022
- 2022-01-21 JP JP2022008032A patent/JP7371144B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019142903A (ja) | 2019-08-29 |
| JP7072538B2 (ja) | 2022-05-20 |
| EP3903820A1 (en) | 2021-11-03 |
| WO2013177596A2 (en) | 2013-11-28 |
| CA3172599A1 (en) | 2013-11-28 |
| JP2015523970A (ja) | 2015-08-20 |
| EP2854850B1 (en) | 2021-05-26 |
| JP2022064935A (ja) | 2022-04-26 |
| ES2879931T3 (es) | 2021-11-23 |
| EP2854850A2 (en) | 2015-04-08 |
| US20220118087A1 (en) | 2022-04-21 |
| JP6761792B2 (ja) | 2020-09-30 |
| CA3172599C (en) | 2025-10-07 |
| JP2018048158A (ja) | 2018-03-29 |
| CA2874673A1 (en) | 2013-11-28 |
| US20150216971A1 (en) | 2015-08-06 |
| WO2013177596A3 (en) | 2014-02-13 |
| CA2874673C (en) | 2022-11-22 |
| AU2013266069B2 (en) | 2018-03-15 |
| JP6257600B2 (ja) | 2018-01-10 |
| JP7371144B2 (ja) | 2023-10-30 |
| US10722577B2 (en) | 2020-07-28 |
| AU2013266069A1 (en) | 2014-11-27 |
| EP2854850A4 (en) | 2016-01-06 |
| EP3903820B1 (en) | 2025-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2854850T3 (da) | Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom | |
| DK2818481T3 (da) | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer | |
| DK2841097T3 (da) | Sammensætninger og fremgangsmåder til behandling og forebyggelse af porcint reproduktions- og respirationssyndrom | |
| DK2532680T3 (da) | Medicinsk sammensætning til behandling og/eller forebyggelse af cancer | |
| DK2898061T3 (da) | Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande | |
| DK3366307T3 (da) | Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri | |
| DK2532366T3 (da) | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer | |
| DK2935303T3 (da) | 4`-fluornukleosider, 4`-fluornukleotider og analoger dertil til behandling af HCV | |
| DK2804587T3 (da) | Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed | |
| DK3082831T3 (da) | Sammensætning på basis af methyl-cyclodextriner til behandling og/eller forebyggelse af sygdomme ved forøgelse af koncentrationen af hdl-kolesterol | |
| DK2981274T3 (da) | Probiotiske stammer til anvendelse ved behandling eller forebyggelse af osteoporose | |
| BR112015001838A2 (pt) | composições de inibidor de efluxo e métodos de tratamento utilizando o mesmo. | |
| DK2819602T3 (da) | Kateter til behandling af atrieflagren med enkelt-virkende dobbelt afbøjningsmekanisme | |
| LT2916860T (lt) | Diabeto gydymui skirta kompozicija, apimanti oksintomodulino analogą | |
| DK3102189T3 (da) | Sammensætning og fremgangsmåde til at fremme søvn | |
| SI3513806T1 (sl) | Sestava imunogena | |
| DK2861273T3 (da) | Anvendelse af heparin og kulhydrater til behandling af cancer. | |
| DK3395353T5 (da) | Plasminogen til anvendelse til behandling eller forebyggelse af diabetes-mellitus-nerveskade | |
| DK3238707T3 (da) | Sammensætninger og fremgangsmåder til behandling af intestinal hyperpermeabilitet | |
| DK2964255T3 (da) | Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI) | |
| DK2961420T3 (da) | Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom | |
| DK2702992T3 (da) | Anvendelse af melatonin til behandling af og/eller forebyggelse af mucositis | |
| DK2791684T3 (da) | Fremgangsmåder til forebyggelse eller behandling af forstyrrelser ved forøgelse af biotilgængeligheden af jern og relateret farmaceutisk formulering | |
| HUE040496T2 (hu) | Vegyületek elhízás kezelésére és alkalmazási eljárásaik | |
| DK3175852T3 (da) | Difluorlactamsammensætninger til EP4-medierede osteorelaterede sygdomme og tilstande |